{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:07:19Z","timestamp":1785391639064,"version":"3.55.0"},"reference-count":46,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,6,7]],"date-time":"2023-06-07T00:00:00Z","timestamp":1686096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of SMEs and Startups (MSS, Republic of Korea)","award":["S3229628"],"award-info":[{"award-number":["S3229628"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>The purpose of this study is to develop and evaluate a self-microemulsifying drug delivery system (SMEDDS) to improve the oral absorption of poorly water-soluble olaparib. Through the solubility test of olaparib in various oils, surfactants and co-surfactants, pharmaceutical excipients were selected. Self-emulsifying regions were identified by mixing the selected materials at various ratios, and a pseudoternary phase diagram was constructed by synthesizing these results. The various physicochemical properties of microemulsion incorporating olaparib were confirmed by investigating the morphology, particle size, zeta potential, drug content and stability. In addition, the improved dissolution and absorption of olaparib were also confirmed through a dissolution test and a pharmacokinetic study. An optimal microemulsion was generated in the formulation of Capmul\u00ae MCM 10%, Labrasol\u00ae 80% and PEG 400 10%. The fabricated microemulsions were well-dispersed in aqueous solutions, and it was also confirmed that they were maintained well without any problems of physical or chemical stability. The dissolution profiles of olaparib were significantly improved compared to the value of powder. Associated with the high dissolutions of olaparib, the pharmacokinetic parameters were also greatly improved. Taken together with the results mentioned above, the microemulsion could be an effective tool as a formulation for olaparib and other similar drugs.<\/jats:p>","DOI":"10.3390\/pharmaceutics15061669","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T01:34:32Z","timestamp":1686188072000},"page":"1669","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Development and Evaluation of Self-Microemulsifying Drug Delivery System for Improving Oral Absorption of Poorly Water-Soluble Olaparib"],"prefix":"10.3390","volume":"15","author":[{"given":"Yong-Han","family":"Kim","sequence":"first","affiliation":[{"name":"College of Pharmacy, Hanyang University, Ansan 15588, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Bo","family":"Kim","sequence":"additional","affiliation":[{"name":"Bio-Living Engineering Major, Global Leaders College, Yonsei University, Seoul 03722, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Hee","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Bio-Health Technology, College of Biomedical Science, Kangwon National University, Chuncheon 24341, Republic of Korea"},{"name":"Department of Bio-Pharmaceutical Engineering, Kangwon National University, Chuncheon 24341, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9657-4399","authenticated-orcid":false,"given":"Thi-Thao-Linh","family":"Nguyen","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Gachon University, Incheon 21936, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hoon","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, College of Pharmacy, Kangwon National University, Chuncheon 24341, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Sun","family":"Moon","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, College of Pharmacy, Kangwon National University, Chuncheon 24341, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwan-Hyung","family":"Cho","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Inje University, Gimhae 50834, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-1917","authenticated-orcid":false,"given":"Tae-Yong","family":"Sim","sequence":"additional","affiliation":[{"name":"Department of Artificial Intelligence, Sejong University, Seoul 05006, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun-Ji","family":"Heo","sequence":"additional","affiliation":[{"name":"Department of Bio-Health Technology, College of Biomedical Science, Kangwon National University, Chuncheon 24341, Republic of Korea"},{"name":"Department of Bio-Pharmaceutical Engineering, Kangwon National University, Chuncheon 24341, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8852-0198","authenticated-orcid":false,"given":"Sung Tae","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Nanoscience and Engineering, Inje University, Gimhae 50834, Republic of Korea"},{"name":"Department of Pharmaceutical Engineering, Inje University, Gimhae 50834, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2431-1327","authenticated-orcid":false,"given":"Hyun-Suk","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Kangwon National University, Chuncheon 24341, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Pil","family":"Jee","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Chosun University, Gwangju 61452, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2318-387X","authenticated-orcid":false,"given":"Han-Gon","family":"Choi","sequence":"additional","affiliation":[{"name":"College of Pharmacy, Hanyang University, Ansan 15588, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Jin","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Bio-Health Technology, College of Biomedical Science, Kangwon National University, Chuncheon 24341, Republic of Korea"},{"name":"Department of Pharmacy, College of Pharmacy, Kangwon National University, Chuncheon 24341, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1208\/s12248-009-9144-x","article-title":"Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World\u2019s Top Oral Drugs","volume":"11","author":"Dahan","year":"2009","journal-title":"AAPS J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejpb.2016.07.006","article-title":"A novel solubilization technique for poorly soluble drugs through the integration of nanocrystal and cocrystal technologies","volume":"107","author":"Karashima","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/pr.112.005660","article-title":"Strategies to Address Low Drug Solubility in Discovery and Development","volume":"65","author":"Williams","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ajps.2014.05.005","article-title":"Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability","volume":"9","author":"Khadka","year":"2014","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2011.08.032","article-title":"Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: Basic approaches and practical applications","volume":"420","author":"Kawabata","year":"2011","journal-title":"Int. J. Pharm."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ijpharm.2015.10.029","article-title":"Solubility enhancement of BCS Class II drug by solid phospholipid dispersions: Spray drying versus freeze-drying","volume":"496","author":"Fong","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_8","first-page":"195727","article-title":"Drug solubility: Importance and enhancement techniques","volume":"2012","author":"Savjani","year":"2012","journal-title":"Int. Sch. Res. Not."},{"key":"ref_9","first-page":"32","article-title":"Enhancement of solubilization and bioavailability of poorly soluble drugs by physical and chemical modifications: A recent review","volume":"2","author":"Chaudhary","year":"2012","journal-title":"J. Adv. Pharm. Educ. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.55522\/jmpas.V1I1.0002","article-title":"Techniques for solubility enhancement of poorly soluble drugs: An overview","volume":"1","author":"Sikarra","year":"2012","journal-title":"JMPAS"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1517\/17425247.2011.606808","article-title":"Oral formulation strategies to improve solubility of poorly water-soluble drugs","volume":"8","author":"Singh","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1517\/17425247.4.4.403","article-title":"Drug delivery strategies for poorly water-soluble drugs","volume":"4","author":"Fahr","year":"2007","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijpharm.2013.03.054","article-title":"Lipid-based formulations for oral administration of poorly water-soluble drugs","volume":"453","author":"Mu","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijpharm.2015.09.009","article-title":"Development of self emulsifying lipid formulations of BCS class II drugs with low to medium lipophilicity","volume":"495","author":"Jannin","year":"2015","journal-title":"Int. J. Pharm."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.apsb.2013.10.001","article-title":"Oral lipid-based drug delivery systems\u2014An overview","volume":"3","author":"Kalepu","year":"2013","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0169-409X(96)00494-2","article-title":"Lipid-based vehicles for the oral delivery of poorly water soluble drugs","volume":"25","author":"Humberstone","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejpb.2017.05.008","article-title":"Novel strategies for the formulation and processing of poorly water-soluble drugs","volume":"126","author":"Lorenz","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ajps.2013.07.012","article-title":"Liposomal formulations for enhanced lymphatic drug delivery","volume":"8","author":"Kim","year":"2013","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2174\/156720109789000519","article-title":"Self micro-emulsifying drug delivery system: Formulation development and biopharmaceutical evaluation of lipophilic drugs","volume":"6","author":"Patel","year":"2009","journal-title":"Curr. Drug Deliv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/S0928-0987(00)00167-6","article-title":"Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and \u2018self-microemulsifying\u2019 drug delivery systems","volume":"11","author":"Pouton","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jconrel.2019.08.008","article-title":"Labrasol\u00ae is an efficacious intestinal permeation enhancer across rat intestine: Ex vivo and in vivo rat studies","volume":"310","author":"McCartney","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jconrel.2009.10.005","article-title":"Impact of emulsion-based drug delivery systems on intestinal permeability and drug release kinetics","volume":"142","author":"Buyukozturk","year":"2010","journal-title":"J. Control. Release"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3109\/10717544.2014.896058","article-title":"Self-microemulsifying drug delivery system (SMEDDS)\u2014Challenges and road ahead","volume":"22","author":"Dokania","year":"2014","journal-title":"Drug Deliv."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4103\/0250-474X.159596","article-title":"Role of components in the formation of self-microemulsifying drug delivery systems","volume":"77","author":"Reddy","year":"2015","journal-title":"Indian J. Pharm. Sci."},{"key":"ref_25","first-page":"75","article-title":"Self micro-emulsifying drug delivery system (SMEDDS)","volume":"3","author":"Kyatanwar","year":"2010","journal-title":"J. Pharm. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijpharm.2007.08.057","article-title":"Stable drug encapsulation in micelles and microemulsions","volume":"345","author":"Narang","year":"2007","journal-title":"Int. J. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-019-0154-9","article-title":"Advances and perspectives of PARP inhibitors","volume":"8","author":"Yi","year":"2019","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.currproblcancer.2010.12.002","article-title":"PARP Inhibitor Treatment in Ovarian and Breast Cancer","volume":"35","author":"Weil","year":"2011","journal-title":"Curr. Probl. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1021\/acs.oprd.7b00235","article-title":"Patent Review of Manufacturing Routes to Recently Approved PARP Inhibitors: Olaparib, Rucaparib, and Niraparib","volume":"21","author":"Hughes","year":"2017","journal-title":"Org. Process. Res. Dev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1208\/s12249-019-1468-y","article-title":"Preparation and Comparison of Oral Bioavailability for Different Nano-formulations of Olaparib","volume":"20","author":"Pathade","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/ajco.12636","article-title":"Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer","volume":"12","author":"Friedlander","year":"2016","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40262-018-0714-x","article-title":"Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients","volume":"58","author":"Zhou","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2017.01.014","article-title":"BCS class IV drugs: Highly notorious candidates for formulation development","volume":"248","author":"Ghadi","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1208\/s12249-008-9080-6","article-title":"Exemestane Loaded Self-Microemulsifying Drug Delivery System (SMEDDS): Development and Optimization","volume":"9","author":"Singh","year":"2008","journal-title":"AAPS PharmSciTech"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ijpharm.2011.02.006","article-title":"Skin penetration and deposition of carboxyfluorescein and temoporfin from different lipid vesicular systems: In vitro study with finite and infinite dosage application","volume":"408","author":"Chen","year":"2011","journal-title":"Int. J. Pharm."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jff.2016.10.007","article-title":"Enhanced oral bioavailability of [6]-Gingerol-SMEDDS: Preparation, in vitro and in vivo evaluation","volume":"27","author":"Xu","year":"2016","journal-title":"J. Funct. Foods"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1021\/acs.langmuir.9b00610","article-title":"Poly-phosphocholinated Liposomes Form Stable Superlubrication Vectors","volume":"35","author":"Lin","year":"2019","journal-title":"Langmuir"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3109\/03602538308991425","article-title":"Dose-Dependent Metabolism, Therapeutic Effect, and Toxicity of Anticancer Drugs in Man","volume":"14","author":"Powis","year":"1983","journal-title":"Drug Metab. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11523-016-0435-8","article-title":"An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib","volume":"11","author":"Mateo","year":"2016","journal-title":"Target. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1590\/S1984-82502015000300024","article-title":"Mucoadhesive microemulsion of ibuprofen: Design and evaluation for brain targeting efficiency through intranasal route","volume":"51","author":"Mandal","year":"2015","journal-title":"Braz. J. Pharm. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Zech, J., Gold, D., Salaymeh, N., Sasson, N.C., Rabinowitch, I., Golenser, J., and M\u00e4der, K. (2020). Oral Administration of Artemisone for the Treatment of Schistosomiasis: Formulation Challenges and In Vivo Efficacy. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12060509"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.vetpar.2010.09.011","article-title":"Effects of artemisinin and Artemisia extracts on Haemonchus contortus in gerbils (Meriones unguiculatus)","volume":"175","author":"Squires","year":"2011","journal-title":"Vet. Parasitol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1208\/s12249-014-0247-z","article-title":"Preformulation studies on solid self-emulsifying systems in powder form containing magnesium aluminometasilicate as porous carrier","volume":"16","author":"Krupa","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"100677","DOI":"10.1016\/j.apmt.2020.100677","article-title":"Polyethylene glycol (PEG) derived carbon dots: Preparation and applications","volume":"20","author":"Peng","year":"2020","journal-title":"Appl. Mater. Today"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/0963689717749032","article-title":"A PEG-based hydrogel for effective wound care management","volume":"27","author":"Chen","year":"2018","journal-title":"Cell Transplant."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/6\/1669\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:49:47Z","timestamp":1760125787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/6\/1669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,7]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["pharmaceutics15061669"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15061669","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,7]]}}}